Form 4 for BLFS BIOLIFE SOLUTIONS INC

Accepted 2024-03-12 00:00:00 ET · period of report 2024-03-08 · accession 0001628280-24-010743 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2024-03-12	2024-03-11+	BLFS	Wichterman Troy	CFO	S - Sale	$16.64	-7,610	135.4K	-5%	-$126.6K
M	2024-03-12	2024-03-08	BLFS	Wichterman Troy	CFO	A - Grant	—	+70.9K	106.5K	+199%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-03-12	S	D	7,249	$16.60	128,134	D	—	—
2	Common	Common Stock	2024-03-11	S	D	361	$17.42	135,383	D	—	—
3	Common	Common Stock	2024-03-08	A	A	29,206	—	135,744	D	—	—	(F2) The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
4	Common	Common Stock	2024-03-08	A	A	41,715	—	106,538	D	—	—	(F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation.